TNF-α -308 promoter polymorphism in patients with rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 34, Issue 1, 2005, Pages 22-26

  Pawlik, Andrzej ^a   Florczak, M ^a   Ostanek, L ^a   Brzosko, M ^a   Brzosko, I ^a   Szklarz, B Gawronska ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HLA DR4 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS;

EID: 15944399122     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 1998;10:187-200.
2. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869-71.
3. Ared WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
4. Cairns AP, Taggart AJ. Anti-tumor necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 2002;71:101-5.
5. Machner A, Baier A, Wille A, Drynda S, Pap G, Drynda A, et al. Higher susceptibility to Fas ligand induced apoptosis and altered modulation of cell death by tumor necrosis factor-α in periarticular tenocytes from patients with knee joint osteoarthritis. Arthritis Res Ther 2003;5:253-61.
6. Robak T, Gladalska A, Stepien H. The tumor necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998;9:145-54.
7. Martinez A, Fernandez-Arquero M, Pascual-Salcedo D, Conejero L, Alves H, Balsa A, et al. Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis. Arthritis Rheum 2000;43:1366-70.
8. Verveij CL. Tumor necrosis factor gene polymorphism as severity markers in rheumatoid arthritis. Ann Rheum Dis 1999;58:120-6.
9. Lacki JK, Moser R, Korczowska I, Mackiewicz S, Muller W. TNF-alpha gene polymorphism does not affect the clinical and radiological outcome of rheumatoid arthritis. Rheumatol Int 2000;19:137-40.
10. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
11. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
12. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphism in interferon-gamma, interleukin-10, transforming growth factor-beta1 and tumor necrosis factor-alpha genes: a technical report. Transpl Immunol 1998;6:193-7.
13. Di GF, Wnuki G, Duff GW. Tumor necrosis factor in synovial exudates. Ann Rheum Dis 1988;47:769-72.
14. Chu CQ, Field M, Feldman M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
15. Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis, V: mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenese production and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest 1990;86:1790-98.
16. Alsalameh S, Winter K, Al-Ward R, Wendler J, Kalden JR, Kinne RW. Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially on the lining layers; TNF-alpha is distributed mainly in the vicinity of TNF-receptors in the deeper layers. Scand J Immunol 1999;49:278-85.
17. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Marini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997;107:507-12.
18. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995;84:433-39.
19. D'Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNF promoter region. Immunogenetics 1994;39:150-4.
20. Wilson AG, Symsons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;93:3195-9.
21. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumor necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6.
22. Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, et al. Identification of three new single nucleotide polymorphism in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998;52:359-67.
23. Hoffmann SC, Stanley EM, Cox ED. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001;72:1444-50.
24. Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995;12:127-33.
25. Wilson AG, de Vries N, van de Putte LB, Duff GW. A tumor necrosis factor alpha polymorphism is not associated with rheumatoid arthritis. Arthritis Rheum Dis 1995; 54:601-3.
26. Trifunovic Cvetkovic J, Wallberg-Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S, Kari Lefvert A. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-α, IL-β and IL-1Ra genes. J Rheumatol 2002;29:212-17.
27. Yen JH, Chen CJ, Tsai WC, Lin CH, Ou TT, Wu CC, et al. Tumor necrosis factor promoter polymorphism in patients with rheumatoid arthritis in Taiwan. J Rheumatol 2001; 28:1788-92.
28. Vinasco J, Beraun Y, Nieto A, Fraile A, Mataran L, Pareja E, et al. Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 1997;49:74-8.
29. Brinkman BM, Huizinga TW, Kurban SS, van der Velde EA, Schreuder GM, Hazes JM, et al. Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 1997;36:516-21.
30. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position - 308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48:1849-52.
31. Barton A, Platt H, Salway F, Symmons D, Barret E, Bukhari M, et al. Polymorphism in the tumor necrosis factor gene is not associated with severity of inflammatory polyarthritis. Ann Rheum Dis 2004;63:280-4.
32. Maury CP, Liljestrom M, Laiho K, Tiitinen S, Kaarela K, Hurme M. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003;48:3068-76.
33. Seki N, Kamizono S, Yamada A, Higuchi T, Matsumoto H, Niiya F, et al. Polymorphism in the 5′-flanking region of tumor necrosis factor-alpha gene in patients with rheumatoid arthritis. Tissue Antigens 1999;54:194-7.